ALX Oncology Holdings Inc. (ALXO) |
|
4.52 -0.04 (-0.88%)
|
03-31 16:00 |
|
Open: |
4.58 |
Pre. Close: |
4.56 |
|
High:
|
4.69 |
Low:
|
4.4925 |
|
Volume:
|
168,399 |
Market Cap:
|
185(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:16:40 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.96  One year: 8.05 |
| Support: |
Support1: 4.44 Support2: 3.69 |
| Resistance: |
Resistance1: 5.96 Resistance2: 6.9 |
| Pivot: |
4.9 |
| Moving Average: |
MA(5): 4.78 MA(20): 5.19
MA(100): 8.91 MA(250): 10.18 |
| MACD: |
MACD(12,26): -0.7  Signal(9): -0.8 |
| Stochastic oscillator: |
%K(14,3): 13.1 %D(3): 17.7 |
| RSI: |
RSI(14): 28.1 |
| 52-week: |
High: 19.22 Low: 4.44 |
| Average Vol(K): |
3-Month: 233 (K) 10-Days: 318 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALXO ] has closed above bottom band by 16.3%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.18 - 5.21 |
5.21 - 5.23 |
|
Low:
|
4.38 - 4.41 |
4.41 - 4.43 |
|
Close:
|
4.52 - 4.56 |
4.56 - 4.6 |
|
Company Description |
|
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California. |
Headline News |
Tue, 14 Mar 2023
ALX Oncology and Quantum Leap Healthcare CollaborativeTM ... - PR Newswire
Mon, 13 Mar 2023
HC Wainwright reduced ALX Oncology (NASDAQ:ALXO) PT to $30.00. - Best Stocks
Fri, 10 Mar 2023
Bay Area biotechs seek to assure investors of minimal SVB ... - The Business Journals
Thu, 09 Mar 2023
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones - Yahoo Finance
Thu, 16 Feb 2023
ALX Oncology Announces First Patient Dosed in ASPEN-07, a ... - GlobeNewswire
Thu, 05 Jan 2023
ALX Oncology Provides Corporate Update and Highlights Key ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
41 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
2.5 (%) |
|
% Held by Institutions
|
101.6 (%) |
|
Shares Short
|
3,840 (K) |
|
Shares Short P.Month
|
3,870 (K) |
Stock Financials |
|
EPS
|
-2.58 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.44 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-23.3 |
|
Return on Equity (ttm)
|
-39.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.12 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-89 (M) |
|
Levered Free Cash Flow
|
-93 (M) |
Stock Valuations |
|
PE Ratio
|
-1.76 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.7 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.08 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
